Topic: Chutes and Ladders
Bluebird Bio taps Heffron as Euro chief; Hildemann joins struggling Ipsen as CMO; Ivenix names Hansen as CEO.
Dr. Steven Hildemann is set to join Parisian biotech Ipsen as its new EVP and chief medical officer as the company looks to overturn a clinical hold.
Pfizer ex-CEO Read picks up job at The Carlyle Group; AMAG dumps CEO Heiden; ex-Lilly chief Conterno joins team at Fibrogen.
Fresh off a $55.5 million round, IFM Therapeutics snagged a new chief scientific officer. Michael Cooke, Ph.D., joins from stem cell biotech Magenta.
AstraZeneca R&D chief Pangalos receives knighthood; Fountain taps Zhen as new CEO; Jones joined McCann Health as creative head.
Pfizer Chairman Read to take Viatris board seat; Bristol's Biondi bolts; Ipsen CEO Meek takes over new company.
Allen Yang, M.D., Ph.D., will now oversee clinical development and operations as Xencor pushes a suite of bispecific antibodies through the clinic.
A new gene therapy spinout has nabbed Ipsen chief executive David Meek to help sell its new drug.
Grail brought on a new chief commercial officer, Illumina's Gautam Kollu, as it steers toward the market.
Pyxis brings on SpringWorks founder Sullivan; Insitro hires chief data officer Batzoglou; Frinzi to step down from J&J Vision.